Hua Medicine (Shanghai) stock closed at HK$2.60 on Friday, roughly flat over the past month but still down about 20% over three months. The market reaction looks cautious. The headline from these H1 2026 numbers is a clear margin and profit squeeze. Revenue reached CNY 378.9m, yet the company still reported a net loss of CNY 30.2m and a trailing twelve month loss of CNY 107.8m.
For a commercial stage biotech built around dorzagliatin, that gap between a growing top line and continuing losses is what will drive the longer term debate on valuation and risk.
Love the potential of Hua Medicine (Shanghai) as a commercial stage biotech but concerned about the ongoing losses and margin pressure? Check out the 292 resilient stocks with low risk scores.
H1 2026 Earnings Summary
- Revenue H1 2026 vs. H1 2025: CNY 378.904m vs. CNY 217.432m (the change reflects higher reported revenue in the latest half)
- Net Income or Loss H1 2026 vs. H1 2025: Loss of CNY 30.195m vs. profit of CNY 1,183.946m (the company moved back into loss making territory)
- Basic EPS H1 2026 vs. H1 2025: Loss of CNY 0.03 per share vs. earnings of CNY 1.202088 per share (this marks a swing from profit to loss per share)
- Trailing Twelve Month Net Income H1 2026 vs. H1 2025: Loss of CNY 107.788m vs. profit of CNY 1,076.043m on a trailing twelve month basis (this represents a shift from sizeable profit to a reported loss)
Prefer clear visuals over scrolling through extensive Hua Medicine (Shanghai) earnings tables and footnotes? See the stock's recent financial performance and profitability trend presented in simple charts and key metrics in our company report for Hua Medicine (Shanghai).
Revenue Momentum Versus Profit Pressure At Hua Medicine
For investors leaning bullish on Hua Medicine, the H1 2026 figures support a commercial traction story around dorzagliatin. Revenue reached CNY 378.9m compared with CNY 217.4m a year earlier, which backs the message of stronger uptake and a broader commercial footprint. Management commentary about higher gross margin potential and controlled R&D spend also points to a business that is trying to scale without losing financial discipline. The narrowing reported net loss versus previous periods suggests the company is at least directionally moving closer to breakeven.
Losses, Single-Asset Risk And Execution Questions
The bear side of the Hua Medicine story still finds support in these numbers. The company moved from a CNY 1,183.9m profit in H1 2025 to a CNY 30.2m loss in H1 2026, and the trailing twelve month result also swung from profit to a CNY 107.8m loss. That shift keeps concerns about cash burn and execution alive, especially for a business concentrated on one commercial asset and a broad early stage pipeline. The 20% share price decline over three months suggests investors have not fully embraced the current trajectory.
Compare Hua Medicine (Shanghai)'s push toward breakeven and dorzagliatin driven revenue story with how institutional analysts are setting expectations. See the consensus price target analysis for Hua Medicine (Shanghai) to check whether the earnings swing back into losses has analysts lifting or cutting their targets.Stay Ahead With Simply Wall St
If Hua Medicine (Shanghai)'s shift from profit to loss has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value and watch for a more attractive entry point. Once you are invested, keep your focus on what really matters by using the Portfolio Command Center to cut out noise and highlight key earnings, valuation and risk updates. For a broader view on how other investors are thinking about Hua Medicine (Shanghai) and similar stocks, tap into shared insights through the Community. This can help you identify potential catalysts and risks earlier and stay a step ahead of the wider market.
Seeking Alternatives Beyond Hua Medicine?
Fresh stock ideas can move from quiet to breakout while you watch from the sidelines. Catch momentum while it matters, before the crowd closes in, and act now.
- Spot companies with steady momentum and limited drawdowns by reviewing a curated group of 292 resilient stocks with low risk scores that aim to keep portfolio swings under control.
- Target income opportunities with staying power by scanning a shortlist of 431 dividend fortresses that could help anchor your returns when markets feel unsettled.
- Pursue early potential in smaller firms by tracking a hand picked pool of 614 high quality undiscovered gems that remain under the radar for now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com